Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 9/20 | 1.00 |
| ▸ | ADRB2 | P07550 | 3/20 | 1.00 |
| ▸ | ADRB1 | P08588 | 2/20 | 1.00 |
| ▸ | HTT | P42858 | 4/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.60 |
| ▸ | LMNA | P02545 | 3/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.60 |
| ▸ | USP2 | O75604 | 2/20 | 0.60 |
| ▸ | PKM | P14618 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | RECQL | P46063 | 1/20 | 0.56 |
| ▸ | HTR6 | P50406 | 2/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30058969 | 1.00 | NCF1 (1.00) | NCF1ADRB2ADRB1HTTMAPK1 | |
| SCHEMBL30511704 | 0.86 | NCF1 (0.97) | NCF1ADRB2ADRB1HTTMAPK1 | |
| SCHEMBL5065450 | 0.84 | NCF1 (0.88) | NCF1ADRB2ADRB1HTTMAPK1 | |
| SCHEMBL8237908 | 0.84 | NCF1 (0.72) | NCF1ADRB2ADRB1HTR6 | |
| SCHEMBL6125246 | 0.83 | NCF1 (0.75) | NCF1ADRB2ADRB1HTTMAPK1 | |
| SCHEMBL1366345 | 0.83 | NCF1 (0.75) | NCF1ADRB2ADRB1HTTMAPK1 | |
| SCHEMBL428165 | 0.82 | NCF1 (0.69) | NCF1ADRB2ADRB1LMNAHSD17B10 | |
| SCHEMBL5093588 | 0.82 | NCF1 (1.00) | NCF1ADRB2ADRB1HTTMAPK1 | |
| SCHEMBL2709861 | 0.82 | NCF1 (1.00) | NCF1ADRB2ADRB1LMNAHSD17B10 | |
| SCHEMBL27613419 | 0.82 | NCF1 (0.74) | NCF1ADRB2ADRB1LMNAHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12479821-B2 | Quinoline compound and use thereof | MBD Co., Ltd. (KR) | 2025-11-25 | — | — | US | disclosed |
| US-12018004-B2 | Carbamate compounds and methods of making and using same | H. LUNDBECK A/S (DK) | 2024-06-25 | — | — | US | disclosed |
| US-20230312499-A1 | CARBAMATE COMPOUNDS AND METHODS OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2023-10-05 | — | — | US | disclosed |
| US-20220402890-A1 | NOVEL QUINOLINE COMPOUND AND USE THEREOF | MBD CO., LTD (KR) | 2022-12-22 | — | — | US | disclosed |
| US-20220402890-A1 | NOVEL QUINOLINE COMPOUND AND USE THEREOF | MBD CO., LTD (KR) | 2022-12-22 | — | — | US | disclosed |
| US-11530189-B2 | Carbamate compounds and methods of making and using same | H. LUNDBECKA/S (DK) | 2022-12-20 | — | — | US | disclosed |
| US-20210369731-A1 | COVALENT TARGETING OF E3 LIGASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-12-02 | — | — | US | disclosed |
| EP-3863642-A1 | COVALENT TARGETING OF E3 LIGASES | The Regents of the University of California (US) | 2021-08-18 | — | — | EP | disclosed |
| US-20210188793-A1 | CARBAMATE COMPOUNDS AND METHODS OF MAKING AND USING SAME | LUNDBECK LA JOLLA RESEARCH CENTER, INC. | 2021-06-24 | — | — | US | disclosed |
| WO-2021123291-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2021-06-24 | — | — | WO | disclosed |
| US-20040106655-A1 | Proline derivatives and the use thereof as drugs | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2004-06-03 | — | — | US | disclosed |
| EP-1385838-A1 | PIPERAZINO-DERIVATIVES AND THEIR USE AS PDE4 INHIBITOR | ALTANA Pharma AG (DE) | 2004-02-04 | — | — | EP | disclosed |
| CN-1441779-A | Proline derivatives and use thereof as drugs | MITSUBISHI PHARMACEUTICAL CO L (JP) | 2003-09-10 | — | — | CN | disclosed |
| EP-1308439-A1 | PROLINE DERIVATIVES AND USE THEREOF AS DRUGS | WELFIDE CORPORATION (JP) | 2003-05-07 | — | — | EP | disclosed |
| WO-2002085885-A1 | PIPERAZINO-DERIVATIVES AND THEIR USE AS PDE4 INHIBITOR | ALTANA PHARMA AG (DE) | 2002-10-31 | — | — | WO | disclosed |
| US-5753659-A | ANTICOAGULANTS FOR BLOOD DISORDER, CARDIOVASCULAR DISORDER, THROMBOSIS, | ZENECA LIMITED (GB) | 1998-05-19 | — | — | US | disclosed |
| US-5750754-A | TERTIARY BUTYL 3-METHYL-4-SUBSTITUTED BUTYRATE; CHEMICAL INTERMEDIATES FOR ANTICAOGULANT DRUGS | ZENECA LIMITED (GB) | 1998-05-12 | — | — | US | disclosed |
| US-5563141-A | INHIBIT CELL ADHESION FOR EXAMPLE, PLATELET AGGRE GATION | ZENECA LIMITED (GB) | 1996-10-08 | — | — | US | disclosed |
| EP-0690847-A1 | HETEROCYCLIC COMPOUNDS AS PLATELET AGGREGATION INHIBITORS | ZENECA LIMITED (GB) | 1996-01-10 | — | — | EP | disclosed |
| WO-1994022835-A2 | HETEROCYCLIC COMPOUNDS AS PLATELET AGGREGATION INHIBITORS | ZENECA LIMITED (GB) | 1994-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11530189-B2 | Carbamate compounds and methods of making and using same | ABHD6, ABHD16A, RABL6 | NCF1 1891/4885ADRB2 4489/4885ADRB1 4498/4885 |
| US-12479821-B2 | Quinoline compound and use thereof | CYP4A11, CYP7A1, CYP4B1 | NCF1 2257/4885ADRB2 1647/4885ADRB1 726/4885 |
| US-20210188793-A1 | CARBAMATE COMPOUNDS AND METHODS OF MAKING AND USING SAME | ABHD6, ABHD16A, RABL6 | NCF1 1891/4885ADRB2 4489/4885ADRB1 4498/4885 |
| US-20220402890-A1 | NOVEL QUINOLINE COMPOUND AND USE THEREOF | CYP4A11, CYP4B1, CYP4A22 | NCF1 2403/4885ADRB2 1242/4885ADRB1 553/4885 |
| US-20040106655-A1 | Proline derivatives and the use thereof as drugs | DPP4, DPP3, DPP7 | NCF1 3736/4885ADRB2 1960/4885ADRB1 981/4885 |
| US-20230312499-A1 | CARBAMATE COMPOUNDS AND METHODS OF MAKING AND USING SAME | ABHD6, ABHD16A, RABL6 | NCF1 1891/4885ADRB2 4489/4885ADRB1 4498/4885 |
| US-20210369731-A1 | COVALENT TARGETING OF E3 LIGASES | RNF114, RNF4, RNF168 | NCF1 3558/4885ADRB2 3894/4885ADRB1 3124/4885 |
| US-12018004-B2 | Carbamate compounds and methods of making and using same | ABHD6, ABHD16A, RABL6 | NCF1 1891/4885ADRB2 4489/4885ADRB1 4498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.